Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 850349-42-7 | MDL No. : | MFCD07779193 |
Formula : | C8H7N3O2 | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | MMKXAIFWQDIXBH-UHFFFAOYSA-N |
M.W : | 177.16 | Pubchem ID : | 17749961 |
Synonyms : |
|
Num. heavy atoms : | 13 |
Num. arom. heavy atoms : | 9 |
Fraction Csp3 : | 0.12 |
Num. rotatable bonds : | 2 |
Num. H-bond acceptors : | 4.0 |
Num. H-bond donors : | 0.0 |
Molar Refractivity : | 44.27 |
TPSA : | 56.49 Ų |
GI absorption : | High |
BBB permeant : | No |
P-gp substrate : | No |
CYP1A2 inhibitor : | Yes |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -6.76 cm/s |
Log Po/w (iLOGP) : | 1.77 |
Log Po/w (XLOGP3) : | 0.88 |
Log Po/w (WLOGP) : | 0.52 |
Log Po/w (MLOGP) : | -0.51 |
Log Po/w (SILICOS-IT) : | 0.25 |
Consensus Log Po/w : | 0.58 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 1.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -1.87 |
Solubility : | 2.37 mg/ml ; 0.0134 mol/l |
Class : | Very soluble |
Log S (Ali) : | -1.65 |
Solubility : | 3.96 mg/ml ; 0.0224 mol/l |
Class : | Very soluble |
Log S (SILICOS-IT) : | -1.79 |
Solubility : | 2.89 mg/ml ; 0.0163 mol/l |
Class : | Soluble |
PAINS : | 0.0 alert |
Brenk : | 0.0 alert |
Leadlikeness : | 1.0 |
Synthetic accessibility : | 1.91 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P280-P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H302 | Packing Group: | N/A |
GHS Pictogram: |
![]() |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
99% | With sodium hydroxide; water; In 1,4-dioxane; at 20.0℃; for 0.75h; | PREPARATIVE EXAMPLE 10; Commercially available Imidazo[l,2-a]pyrazine-8-carboxylic acid methyl ester (337 mg) was dissolved in 1,4-dioxane (25 ml) and H2O (58 ml) and treated with 1 M NaOH (2.4 ml). The mixture was stirred at room temperature for 45 Min and the solvents evaporated to afford the crude title compound (MH+ = 164). |
[ 13457-23-3 ]
Methyl 6-bromo-3-(methylamino)pyrazine-2-carboxylate
Similarity: 0.79
[ 16298-03-6 ]
Methyl 2-aminopyrazine-3-carboxylate
Similarity: 0.78
[ 6966-01-4 ]
Methyl 3-amino-6-bromopyrazine-2-carboxylate
Similarity: 0.70
[ 1458-03-3 ]
Methyl 3-amino-6-chloropyrazine-2-carboxylate
Similarity: 0.69
[ 1458-16-8 ]
Methyl 3-amino-6-iodopyrazine-2-carboxylate
Similarity: 0.67
[ 1369160-12-2 ]
6,7-Dihydro-5H-pyrrolo[1,2-a]imidazole-6-carboxylic acid
Similarity: 0.61
[ 133427-07-3 ]
Methyl imidazo[1,2-a]pyridine-8-carboxylate
Similarity: 0.61
[ 1965310-16-0 ]
6,7-Dihydro-5H-pyrrolo[1,2-a]imidazole-6-carboxylic acid hydrochloride
Similarity: 0.60
[ 908581-18-0 ]
Methyl 6-bromoimidazo[1,2-a]pyridine-8-carboxylate
Similarity: 0.59
[ 133427-08-4 ]
Imidazo[1,2-a]pyridine-8-carboxylic acid
Similarity: 0.57